乙酰化修饰对肿瘤相关信号通路的调控及其在肿瘤治疗中潜在应用的研究进展

doi:10.13481/j.1671-587X.20260431

Abstract

Abstract:

Acetylation modification is an important type of post-translational acylation modification for protein. Under the dynamic regulation of histone acetyltransferase （HAT） and histone deacetylase （HDAC）， it affects the biological functions of proteins， and thereby alters the activation state of tumor-related signaling pathways. Consequently， acetylation modification plays a dual role in tumorigenesis and tumor progression， exhibiting both oncogenic and tumor-suppressive effects in various types of cancer. Drawing on recent literatures， this review systematically elucidated the potential molecular mechanisms involved in the regulation of tumor occurrence and development by acetylation modification， focusing on its regulatory effects on key signaling pathways， as well as its impact on crucial biological processes such as tumor cell proliferation， differentiation， metabolism， and apoptosis. Additionally， it further summarized the progress in the application of HDAC inhibitor （HDACi） in tumor therapy， elucidated therapeutic strategies targeting histone or non-histone deacetylation sites， and discussed the significance and potential clinical value. Acetylation modification influences the biological behavior of tumor by regulating the key signaling pathways. HDACi interferes with tumor progression by increasing the acetylation levels of target proteins， and its mechanism is related to the regulation of acetylation modifications in key signaling pathways.

Key words: Acetylation modification, Signaling pathway, Tumor, Histone deacetylase inhibitor, Targeted therapy

CLC Number:

R73-36

Qian AO,Nan LIANG,Hui SUN. Research progress in regulation of tumor-related signaling pathways by acetylation modification and its potential applications in tumor therapy[J].Journal of Jilin University(Medicine Edition), 2026, 52(4): 1179-1186.

References 55

[1]	ALLFREY V G， FAULKNER R， MIRSKY A E. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis［J］. Proc Natl Acad Sci U S A， 1964， 51（5）： 786-794.
[2]	XIA L C， KONG X G， SONG H F， et al. Advances in proteome-wide analysis of plant lysine acetylation［J］. Plant Commun， 2022， 3（1）： 100266.
[3]	LIU Y X， YANG H， LIU X C， et al. Protein acetylation： a novel modus of obesity regulation［J］. J Mol Med （Berl）， 2021， 99（9）： 1221-1235.
[4]	NARITA T， WEINERT B T， CHOUDHARY C. Functions and mechanisms of non-histone protein acetylation［J］. Nat Rev Mol Cell Biol， 2019， 20（3）： 156-174.
[5]	SHANG S， LIU J， HUA F. Protein acylation： mechanisms， biological functions and therapeutic targets［J］. Sig Transduct Target Ther， 2022， 7（1）： 396.
[6]	ZHONG Z X， JIAO Z H， YU F X. The Hippo signaling pathway in development and regeneration［J］. Cell Rep， 2024， 43（3）： 113926.
[7]	FU M Y， HU Y， LAN T X， et al. The Hippo signalling pathway and its implications in human health and diseases［J］. Sig Transduct Target Ther， 2022， 7（1）： 376.
[8]	YANG S Y， XU W Z， LIU C， et al. LATS1 K751 acetylation blocks activation of Hippo signalling and switches LATS1 from a tumor suppressor to an oncoprotein［J］. Sci China Life Sci， 2022， 65（1）： 129-141.
[9]	JIN J Q， ZHANG L， LI X Y， et al. Oxidative stress-CBP axis modulates MOB1 acetylation and activates the Hippo signaling pathway［J］. Nucleic Acids Res， 2022， 50（7）： 3817-3834.
[10]	TANG W F， LI M， YANGZHONG X T， et al. Hippo signaling pathway and respiratory diseases［J］. Cell Death Discov， 2022， 8（1）： 213.
[11]	XIE W L， ZHANG Y Q， WANG B Y， et al. Tripartite motif containing 24 regulates cell proliferation in colorectal cancer through YAP signaling［J］. Cancer Med， 2020， 9（17）： 6367-6376.
[12]	HERQUEL B， OUARARHNI K， DAVIDSON I. The TIF1α-related TRIM cofactors couple chromatin modifications to transcriptional regulation， signaling and tumor suppression［J］. Transcription， 2011， 2（5）： 231-236.
[13]	ZHANG L W， CHEN H， DING B J， et al. High expression of TRIM24 predicts worse prognosis and promotes proliferation and metastasis of epithelial ovarian cancer［J］. J Ovarian Res， 2022， 15（1）： 19.
[14]	KIM G， BHATTARAI P Y， LIM S C， et al. Sirtuin 5-mediated deacetylation of TAZ at K54 promotes melanoma development［J］. Cell Oncol， 2024， 47（3）： 967-985.
[15]	LUO M X， XU Y J， CHEN H F， et al. Advances of targeting the YAP/TAZ-TEAD complex in the hippo pathway for the treatment of cancers［J］. Eur J Med Chem， 2022， 244： 114847.
[16]	HU L F， CHEN W， QIAN A R， et al. Wnt/β-catenin signaling components and mechanisms in bone formation， homeostasis， and disease［J］. Bone Res， 2024， 12（1）： 39.
[17]	YU X M， WANG M H， WU J J， et al. ZNF₃26 promotes malignant phenotype of glioma by up-regulating HDAC7 expression and activating Wnt pathway［J］. J Exp Clin Cancer Res， 2020， 39（1）： 14.
[18]	LI G P， CHOI J E， KRYCZEK I， et al. Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy［J］. Cancer Cell， 2023， 41（2）： 304-322.
[19]	WANG H， QIU Y Q， ZHANG H H， et al. Histone acetylation by HBO1 （KAT7） activates Wnt/β-catenin signaling to promote leukemogenesis in B-cell acute lymphoblastic leukemia［J］. Cell Death Dis， 2023， 14（8）： 498.
[20]	GLAVIANO A， FOO A S C， LAM H Y， et al. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer［J］. Mol Cancer， 2023， 22（1）： 138.
[21]	WEI E D， MITANOSKA A， O’BRIEN Q， et al. Pharmacological targeting of P300/CBP reveals EWS： FLI1-mediated senescence evasion in Ewing sarcoma［J］. Mol Cancer， 2024， 23（1）： 222.
[22]	NIU J， LI W， LIANG C， et al. EGF promotes DKK1 transcription in hepatocellular carcinoma by enhancing the phosphorylation and acetylation of histone H3［J］. Sci Signal， 2020， 13（657）： eabb5727.
[23]	DANG W， BIAN R， FAN Q Q， et al. KIF11 promotes cell proliferation via ERBB2/PI3K/AKT signaling pathway in gallbladder cancer［J］. Int J Biol Sci， 2021， 17（2）： 514-526.
[24]	GAO W T， LU J J， YANG Z T， et al. Mitotic functions and characters of KIF11 in cancers［J］. Biomolecules， 2024， 14（4）： 386.
[25]	GUO X H， ZHOU L， WU Y N， et al. KIF11 as a potential pan-cancer immunological biomarker encompassing the disease staging， prognoses， tumor microenvironment， and therapeutic responses［J］. Oxid Med Cell Longev， 2022， 2022： 2764940.
[26]	ZHENG Y， WU C， YANG J M， et al. Insulin-like growth factor 1-induced enolase 2 deacetylation by HDAC3 promotes metastasis of pancreatic cancer［J］. Sig Transduct Target Ther， 2020， 5（1）： 53.
[27]	SHI J， MIAO D J， LV Q Y， et al. ENO₂ as a biomarker regulating energy metabolism to promote tumor progression in clear cell renal cell carcinoma［J］. Biomedicines， 2023， 11（9）： 2499.
[28]	SHI Q M， XUE C， ZENG Y F， et al. Notch signaling pathway in cancer： from mechanistic insights to targeted therapies［J］. Sig Transduct Target Ther， 2024， 9（1）： 128.
[29]	ZHOU B H， LIN W L， LONG Y L， et al. Notch signaling pathway： architecture， disease， and therapeutics［J］. Sig Transduct Target Ther， 2022， 7（1）： 95.
[30]	EDELMANN J. NOTCH1 Signalling： a key pathway for the development of high-risk chronic lymphocytic leukaemia［J］. Front Oncol， 2022， 12： 1019730.
[31]	FERRANTE F， GIAIMO B D， BARTKUHN M， et al. HDAC3 functions as a positive regulator in Notch signal transduction［J］. Nucleic Acids Res， 2020， 48（7）： 3496-3512.
[32]	SUBRAMANI P， NAGARAJAN N， MARIARAJ S， et al. Knockdown of sirtuin6 positively regulates acetylation of DNMT1 to inhibit NOTCH signaling pathway in non-small cell lung cancer cell lines［J］. Cell Signal， 2023， 105： 110629.
[33]	HUANG Y H， CAI K， XU P P， et al. CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis［J］. Sig Transduct Target Ther， 2021， 6（1）： 10.
[34]	YEH C H， BELLON M， NICOT C. FBXW7： a critical tumor suppressor of human cancers［J］. Mol Cancer， 2018， 17（1）： 115.
[35]	HE Z W， WANG J， XU J， et al. Dynamic regulation of KIF15 phosphorylation and acetylation promotes focal adhesions disassembly in pancreatic cancer［J］. Cell Death Dis， 2022， 13（10）： 896.
[36]	WEI R F， ZHU Y， ZHANG Y J， et al. AIMP1 promotes multiple myeloma malignancy through interacting with ANP32A to mediate histone H3 acetylation［J］. Cancer Commun， 2022， 42（11）： 1185-1206.
[37]	YANG X J， LU B， SUN X Q， et al. ANP32A regulates histone H3 acetylation and promotes leukemogenesis［J］. Leukemia， 2018， 32（7）： 1587-1597.
[38]	BI L， REN Y D， FENG M X， et al. HDAC11 regulates glycolysis through the LKB1/AMPK signaling pathway to maintain hepatocellular carcinoma stemness［J］. Cancer Res， 2021， 81（8）： 2015-2028.
[39]	SHIMADA T， YABUKI Y， NOGUCHI T， et al. The distinct roles of LKB1 and AMPK in p53-dependent apoptosis induced by cisplatin［J］. Int J Mol Sci， 2022， 23（17）： 10064.
[40]	WANG L， BAI Y N， CAO Z M， et al. Histone deacetylases and inhibitors in diabetes mellitus and its complications［J］. Biomedecine Pharmacother， 2024， 177： 117010.
[41]	SHANMUKHA K D， PALUVAI H， LOMADA S K， et al. Histone deacetylase （HDACs） inhibitors： Clinical applications［J］. Prog Mol Biol Transl Sci， 2023， 198： 119-152.
[42]	LI Y X， SETO E. HDACs and HDAC inhibitors in cancer development and therapy［J］. Cold Spring Harb Perspect Med， 2016， 6（10）： a026831.
[43]	PARVEEN R， HARIHAR D， CHATTERJI B P. Recent histone deacetylase inhibitors in cancer therapy［J］. Cancer， 2023， 129（21）： 3372-3380.
[44]	ZHU M， HAN Y L， GU T N， et al. Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway［J］. Cell Rep， 2024， 43（4）： 114065.
[45]	KONG Y J， REN W L， FANG H， et al. Histone deacetylase inhibitors （HDACi） promote KLF5 ubiquitination and degradation in basal-like breast cancer［J］. Int J Biol Sci， 2022， 18（5）： 2104-2115.
[46]	LUO Y， CHEN C S. The roles and regulation of the KLF5 transcription factor in cancers［J］. Cancer Sci， 2021， 112（6）： 2097-2117.
[47]	LIU S N， ZOU Q， CHEN J P， et al. Targeting enhancer reprogramming to mitigate MEK inhibitor resistance in preclinical models of advanced ovarian cancer［J］. J Clin Invest， 2021， 131（20）： e145035.
[48]	SAISOMBOON S， KARIYA R， MAHALAPBUTR P， et al. Augmented global protein acetylation diminishes cell growth and migration of cholangiocarcinoma cells［J］. Int J Mol Sci， 2024， 25（18）： 10170.
[49]	MANNA P R， MOLEHIN D， AHMED A U， et al. Acetylation of steroidogenic acute regulatory protein sensitizes 17β-estradiol regulation in hormone-sensitive breast cancer cells［J］. Int J Mol Sci， 2024， 25（16）： 8732.
[50]	NEBBIOSO A， CARAFA V， CONTE M， et al. C-myc modulation and acetylation is a key HDAC inhibitor target in cancer［J］. Clin Cancer Res， 2017， 23（10）： 2542-2555.
[51]	LIU X X， CHEN Y W， LI Y， et al. A novel class I HDAC inhibitor， AW01178， inhibits epithelial-mesenchymal transition and metastasis of breast cancer［J］. Int J Mol Sci， 2024， 25（13）： 7234.
[52]	PARK E Y， WOO Y， KIM S J， et al. Anticancer effects of a new SIRT inhibitor， MHY2256， against human breast cancer MCF-7 cells via regulation of MDM2-p53 binding［J］. Int J Biol Sci， 2016， 12（12）： 1555-1567.
[53]	DE U， SON J Y， SACHAN R C， et al. A new synthetic histone deacetylase inhibitor， MHY2256， induces apoptosis and autophagy cell death in endometrial cancer cells via p53 acetylation［J］. Int J Mol Sci， 2018， 19（9）： 2743.
[54]	BAI M， CUI M Q， LI M Y， et al. Discovery of a novel HDACi structure that inhibits the proliferation of ovarian cancer cells in vivo and in vitro ［J］. Int J Biol Sci， 2021， 17（13）： 3493-3507.
[55]	SU W J， ZENG L F， CHEN W D. Moscatilin suppresses the breast cancer both in vitro and in vivo by inhibiting HDAC3［J］. Dose Response， 2021， 19（1）： 15593258211001251.

Research progress in regulation of tumor-related signaling pathways by acetylation modification and its potential applications in tumor therapy

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References 55

Related Articles 15

Metrics

Comments

Recommended 0

[1]	Feida YAN,Mingdi CHEN,Zhiwei LIANG. Inhibitory effect of TPX2 silencing on immune escape in non-small cell lung cancer A549 cells by regulating Wnt/β-catenin signaling pathway [J]. Journal of Jilin University(Medicine Edition), 2026, 52(4): 1011-1021.
[2]	Rui LI,Xiaoyan HAO,Liu YANG,Jiayun LIU,Mu HE. Construction and validation of machine learning-based prediction models for esophageal cancer using routine clinical laboratory data [J]. Journal of Jilin University(Medicine Edition), 2026, 52(4): 1086-1095.
[3]	Pingxu AN,Qi HUANG,Xinyu HONG. Research progress in immunotherapy and anti-angiogenic therapy under pituitary adenoma tumor microenvironment [J]. Journal of Jilin University(Medicine Edition), 2026, 52(4): 1170-1178.
[4]	Gengfei CAO, SHAYA·Mahati,Junpeng GU,Weizheng JI, ASIHAER·Hasimu,Weixin REN. Differences in immune microenvironment between DEB-TACE and c-TACE in treatment of hepatocellular carcinoma and mechanism of TRADD-mediated Th17 differentiation [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 764-780.
[5]	Changfeng LIU,Guangjun JIN,Yonggang WANG. Primary renal angiosarcoma with multiple abdominal haemorrhages： A case repert and literature review [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 821-827.
[6]	Qiuping SU,Lei XING,Wei ZHANG,Shan JIANG,Yangyang ZHAO,Fangfang CHEN. Research progress in anti-tumor mechanism of berberine and application of its novel nano-delivery system in tumor therapy [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 863-871.
[7]	Yang YU,Sheyu YE,Kexin WEI,Zhicheng WANG. Research progress in formation mechanism of tumor radioresistance and inhibitory effect of low-dose radiotherapy combination with novel sensitization strategies on tumor radioresistance [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 872-880.
[8]	Xiqian ZHANG,Zhibo DANG,Yunan DU,Pei WU,Hang XIE,Gaofeng TAN. Inhibitory effect of Chaiqi Yigan formula on malignant biological behaviors of liver cancer HepG2 cells by regulating macrophage polarization [J]. Journal of Jilin University(Medicine Edition), 2026, 52(2): 398-409.
[9]	Yu ZHAO,Xiaoshuang HE,Xiaoyin DONG,Fengyi GAO,Jiageng HE. Regulatory effect of lncRNA urothelial carcinoembryonic antigen 1 on anoikis in human gastrointestinal stromal tumor cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2026, 52(2): 429-439.
[10]	Ruihan GE,Chen LI,Shengpeng WANG,Yang LU,Caixia TAN,Haotian CUI,Xinmin WANG,Le ZHANG. Bioinformatic analysis on regulatory mechanism of MAPK-Mcl-1 signaling pathway and macrophage polarization during Bacillus Calmette-Guérin infection and its experimental validation [J]. Journal of Jilin University(Medicine Edition), 2026, 52(2): 440-450.
[11]	Shuangji LI,He SHI,Yiwen QIN,Xiang LI,Yuyang LI,Weiwei LIU,Jia LI. Desmoplastic fibroma of mandible: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2026, 52(1): 246-251.
[12]	Dongxin JIANG, Yunqian LI. Research progress in clinical diagnosis and treatment of oligodendroglioma [J]. Journal of Jilin University(Medicine Edition), 2026, 52(1): 272-280.
[13]	Luyao WANG,Chenxi ZHAO,Jincheng DU,Linlin LIU. Research progress in effect of Toll-like receptor 7/8 on occurrence and development of tumor [J]. Journal of Jilin University(Medicine Edition), 2026, 52(1): 264-271.
[14]	Zhongzheng LIU,Shubo LIAN,Wenxuan FENG,Xin WEN,Hanyu LIU,Wei HE. Prometive effect of knockdown of KIF3B gene on autophagy in mouse embryonic palatal mesenchymal cells by inhibiting Shh signaling pathway [J]. Journal of Jilin University(Medicine Edition), 2025, 51(6): 1445-1451.
[15]	Qu ZHENG,Baoqiang DONG,Xingxing LIN,Xuefeng GUAN,Yu ZHANG,Chaojie WANG,Yiyan Han. Effect of acupuncture on differentiation and apoptosis of quadriceps muscle satellite cells in knee osteoarthritis model rats and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2025, 51(6): 1475-1486.